A Phase 2 (a), Dose-Blinded, Block Randomized Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers

Grants and Contracts Details

StatusFinished
Effective start/end date6/1/06 → 7/30/11

Funding

  • PPD Development Inc: $335,220.00